The role of metabolic syndrome in the course and outcome of NSAID-gastropathy

Mikhail A. Osadchuk; Vladimir A. Reshetnikov; Anastasiya A. Hudarova; Inna N. Vasil’eva; Maxim V. Trushin

Mikhail A. Osadchuk The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia
Vladimir A. Reshetnikov The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia
Anastasiya A. Hudarova The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia
Inna N. Vasil’eva The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia
Maxim V. Trushin Kazan Federal University, Kazan, Russia.

Keywords: NSAID-gastropathy, metabolic syndrome, NSAIDs.

Abstract

Metabolic syndrome is a significant global problem. Many of these patients have to take NSAIDs for a long time as a baseline treatment for associated diseases, the side effects of which on the gastric mucosa known to many specialists. The purpose of the study was to determine the role of metabolic syndrome in the course and outcome of NSAID-gastropathy. Selected 84 patients from 44 to 69 years, divided into 3 groups: 1 group - 31 people with NSAID-gastropathy and MS, 2 group - 24 people with NSAID-gastropathy and without MS, 3 group - 33 patients with MS, taking NSAIDs without NSAID gastropathy. Clinical and anamnestic data were determined, anthropometric parameters were assessed, the biochemical blood test was performed to determine the lipid spectrum, fasting capillary blood glucose level and esophagogastroduodenoscopy (EGDS) – before and 4 weeks after therapy with proton pump inhibitors (PPI) for all subjects.
Data processing performed using the software package Excel, Annova and Statistica 10.
The process of GM erosions healing in subjects with MS and NSAID-gastropathy takes a longer period. The dominant factors in the development of erosive lesions are the levels of HDL cholesterol, degree of hypertension and H. pylori infection. Duration of treatment is mainly influenced by LDL cholesterol levels, TG and TH levels, and the degree of AH. Conclusions. MS makes a negative contribution during NSAID gastropathy.

Downloads

Download data is not yet available.

Author Biographies

Mikhail A. Osadchuk, The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia

The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia

Vladimir A. Reshetnikov, The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia

The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia

Anastasiya A. Hudarova, The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia

The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia

Inna N. Vasil’eva, The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia

The Federal State Autonomous Education Institution of Higher Training, The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation (Sechenovskiy University), Moscow, Russia

Maxim V. Trushin, Kazan Federal University, Kazan, Russia.

Kazan Federal University, Kazan, Russia.

References

1. Alberti K.G., Zimmet P, Shaw J. (April 2005). A new worldwide definition of the metabolic syndrome. Alberti K.G. Consensus from the International Diabetes Federation could help stop the cardiovascular disease time bomb. IDF definition of the metabolic syndrome. Berlin.

2. Almazov V.A., Blagosklonnaya Y.V., Shlyakhto E.V. (1999). Metabolic cardiovascular syndrome. [Metabolicheskiy serdechno-sosudistyy sindrom]- Izdatel'stvo SPbGMU, 208 p. (In Russ).

3. Almazov V.A., Arabidze G.G., Belousov Yu.B. (2000). Prevention, diagnosis and treatment of primary arterial hypertension in the Russian Federation [Profilaktika, diagnostika i lechenie pervichnoy arterial'noy gipertonii v Rossiyskoy Federatsii](DAG1). Klinicheskaya farmakologiya i terapiya. 2000 (3), pp. 3 - 51 (In Russ.).

4. Fernández-Alfonso M.S., Gil-Ortega M., García-Prieto C.F., Mechanisms of Perivascular Adipose Tissue Dysfunction in Obesity. International Journal of Endocrinology, pp. 1-8.

5. Jonathan Q Purnell. (14 April 2018). Obesity and overweight. Definitions, Classification, and Epidemiology of Obesity. World Health Organization.

6. Kalantari S., Khalili D., Asgari S. (2017). Predictors of early adulthood hypertension during adolescence: a population-based cohort study. BMC Public Health, 17(1) 915 p.

7. Karateev AE, Nasonov EL. (2006). The use of nonsteroidal anti-inflammatory drugs. Clinical guidelines [Ispol'zovanie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii]. Rossiyskiy meditsinskiy zhurnal, (14) 1769 p. (In Russ.).

8. Khlynova O.V., Tuev A.V., Beresneva L.N. (2013). The problem of comorbidity, taking into account the state of the cardiovascular system in patients with arterial hypertension and acid-related diseases [Problema komorbidnosti s uchetom sostoyaniya serdechno-sosudistoy sistemy u patsientov s arterial'noy gipertenziey i kislotozavisimymi zabolevaniyami Kazanskiy meditsinskiy zhurnal, 94(1). (In Russ.).

9. Mamedov M.N, Organov R.G. (2005). Metabolic syndrome in real clinical and outpatient settings: principles of diagnosis and treatment [Metabolicheskiy sindrom v real'nykh klinicheskikh i ambulatornykh usloviyakh: printsipy diagnostiki i lecheniya] Profilaktika zabolevaniy i ukreplenie zdorov'ya. (6), pp. 41-45 (In Russ.).

10. Mel'nichenko G.A., Pyshkina E.A. (2001). Obesity and insulin resistance as a risk factors and an integral part of the metabolic syndrome [Ozhirenie i insulinorezistentnost' kak faktory riska i neot"emlemaya chast' metabolicheskogo sindroma]. Terapevticheskiy arkhiv, (12), pp. 5–8 (In Russ.).

11. Murakami K., Fujioka T., Kodama R. (1997). Helicobacter pylori infection accelerates human gastric mucosal cell proliferation. J Gastroenterol. Vol. 32(2), pp. 184-8.

12. Nilsson P.M., Boutouyrie P., Cunha P. (2013). Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. Vol. 31(8), pp. 1517-26.

13. Polikarpov A.V. Aleksandrova G.A. (July 2018). The overall incidence of the entire population of Russia in 2017. Polikarpov A.V. Ministry of Health of the Russian Federation. Russia.

14. Simon C. Johnson, Peter S. Rabinovitch, Matt Kaeberlein. (2013). mTOR is a key modulator of ageing and age-related disease. Nature. (493), pp. 338-345.

15. Smirnov Yu. V., Oslopov V. N., Bilig, I. L. (1990). Epidemiological aspects of the combination of arterial hypertension and peptic ulcer [Epidemiologicheskie aspekty sochetaniya arterial'noy gipertonii i yazvennoy bolezni]. Terapevticheskiy arkhiv, (2), pp. 48 – 52 (In Russ).

16. Strachunsky L.S., Kozlov S.N. (2017). Nonsteroidal anti-inflammatory drugs. Guidance manual [Nesteroidnye protivovospalitel'nye preparaty. Prakticheskoe rukovodstvo]. (In. Russ.).

17. Tokareva Z.N., Mamedov M.N., Deev A.D. (2010). Prevalence and specific features of metabolic syndrome in urban adult population [Rasprostranennost' i osobennosti metabolicheskogo sindroma u vzroslogo gorodskogo naseleniya]. Serdechno-sosudistaya terapiya i profilaktika, Vol. 9(1), pp. 10-14 (In Russ.).

18. Uemura N., Sugano K., Hiraishi H. (2014). Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol. Vol. 49(5), pp. 814-24.